The disclosure belongs to the technical field of material science, and particularly relates to a method for preparing a high sensitivity temperature sensitive reversible color-changing microcapsule. According to the method, a series of novel fluorane dyes are designed and synthesized, the color-changing performance can be achieved without a color developing agent, the fluorane dyes are compounded with a phase change material according to a certain proportion, a series of two-component reversible temperature sensitive color-changing dyes are prepared, and then a two-component reversible thermochromic microcapsule with good color performance and color-changing response performance is prepared by adopting a solvent evaporation method. The two-component reversible thermochromic microcapsule provided by the disclosure can effectively alleviate the color lag phenomenon of a traditional three-component thermochromic capsule.

A process for forming microspheres is disclosed. The process includes contacting a solvent with a modified cellulose to form a solution; contacting the modified cellulose solution with at least one bioactive agent to form a discontinuous phase liquid; contacting the discontinuous phase liquid with a continuous phase liquid to form an emulsion; and contacting the emulsion with a third phase liquid to extract the solvent from the emulsion, thereby forming a plurality of modified cellulose microspheres.

Methods of making personal care compositions including microcapsules and methods of enhancing the efficacy of the microcapsules in said personal care compositions.

The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

The present invention provides polymersomes comprising amphiphilic block-copolymers and their use to quantify ammonia in samples (e.g., body fluid samples). More particularly, it provides a polymersome comprising (a) a membrane, which comprises a block copolymer of poly(styrene) (PS) and poly(ethylene oxide) (PEO), wherein the PS/PEO molecular weight ratio is higher than 1.0 and lower than 4.0; and (b) a core which encloses an acid and at least one pH-sensitive dye. Compositions, strips and kits comprising the polymersomes are also provided along with methods of quantifying ammonia in a sample using the polymersomes, compositions and kit.

A process for forming microspheres is disclosed. The process includes contacting a solvent with a modified cellulose to form a solution; contacting the modified cellulose solution with at least one bioactive agent to form a discontinuous phase liquid; contacting the discontinuous phase liquid with a continuous phase liquid to form an emulsion; and contacting the emulsion with a third phase liquid to extract the solvent from the emulsion, thereby forming a plurality of modified cellulose microspheres.

Methods of making personal care compositions including microcapsules and methods of enhancing the efficacy of the microcapsules in said personal care compositions.

The present disclosure is a cationic electrodeposition coating composition comprising an emulsion particle (A) containing a Michael addition reaction donor component and an emulsion particle (B) containing a Michael addition reaction acceptor component wherein a Michael addition reaction catalyst (C) is contained in the emulsion particle (A) or the emulsion particle (B) or is contained in the cationic electrodeposition coating composition by being microencapsulated.

A process for forming microspheres is disclosed. The process includes contacting a solvent with a modified cellulose to form a solution; contacting the modified cellulose solution with at least one bioactive agent to form a discontinuous phase liquid; contacting the discontinuous phase liquid with a continuous phase liquid to form an emulsion; and contacting the emulsion with a third phase liquid to extract the solvent from the emulsion, thereby forming a plurality of modified cellulose microspheres.

A Provided herein is a benefit agent delivery particle having a core-shell structure in which a shell of polymeric material entraps a core containing benefit agent, and the shell includes a recycled polymer.